FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New on NCI’s Websites for September 2022 September 21, 2022 Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A October 3, 2023 EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 Load more HOT NEWS How People With Advanced Cancer Can Find Meaning Toward the End... Hormone Therapy Has A Stronger Impact On A Woman’s Quality Of... EMA Recommends Extension of Therapeutic Indications for Enzalutamide No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib...
